A. Virone-Oddos

发表

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.

D. Wiederschain, H. van de Velde, M. Chiron, 2021, Blood.

Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2

F. Lacroix, C. Bougeret, T. Huet, 2000, Cancer Gene Therapy.

Concomitant Inhibition of PI 3 K b andBRAForMEK in PTEN-De fi cient / BRAF-Mutant Melanoma Treatment : Preclinical Assessment of SAR 260301 Oral PI 3 K b-Selective Inhibitor H el

C. García-echeverría, C. Lengauer, L. Vincent, 2016 .

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

D. Wiederschain, S. Guérif, V. Blanc, 2021, Oncoimmunology.

In vitro and in vivo effects of UP 269‐6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation

A. Virone-Oddos, A. Cloarec, M. Cazes, 1997, British journal of pharmacology.

Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression.

O. Cochet, W. Fridman, B. Tocqué, 1998, Cancer research.

852 Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC

M. Chiron, C. Nicolazzi, É. Vivier, 2021, Journal for ImmunoTherapy of Cancer.

Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors.

J. Nicolas, C. García-echeverría, C. Lengauer, 2014, Bioorganic & medicinal chemistry letters.

Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Journal of medicinal chemistry.

Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.

J. Teulon, E. Nicolaï, M. Kirchner, 1994, Journal of medicinal chemistry.

Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.

Jean-Pierre Marquette, Magali Mathieu, Thomas Bertrand, 2014, Journal of medicinal chemistry.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells

M. Kersten, A. Kater, M. Spaargaren, 2016, Leukemia.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells

M. Kersten, A. Kater, M. Spaargaren, 2016, Leukemia.

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

C. Nicolazzi, É. Vivier, A. Bauchet, 2023, Nature Biotechnology.

Abstract 5641: CD28 expression on multiple myeloma cells enhances the cytotoxic activity of CD38/CD28xCD3 trispecific T cell engager

M. Chiron, Lan Wu, L. Vidard, 2020 .

N6-substituted adenosine receptor agonists. Synthesis and pharmacological activity as potent antinociceptive agents.

J. Teulon, T. Güngör, A. Virone-Oddos, 1994, Journal of medicinal chemistry.

In vitro pharmacological characterization of UP 269‐6, a novel nonpeptide angiotensin II receptor antagonist

A. Virone-Oddos, C. Delchambre, A. Cloarec, 1995, Fundamental & clinical pharmacology.

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor

C. García-echeverría, C. Lengauer, L. Vincent, 2016, Molecular Cancer Therapeutics.

Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Bioorganic & medicinal chemistry letters.

Abstract 4209: CD38KO K-NK cells prevent NK cell fratricide effect and improve isatuximab-mediated cytotoxicity against multiple myeloma cells

E. Slinger, A. Virone-Oddos, Marco Meloni, 2022, Cancer Research.